The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
Open accessAbstract
Fibroblast activation protein (FAP) is a candidate universal target antigen because it has been reported to be selectively expressed in nearly all solid tumors by a subset of immunosuppressive tumor stromal fibroblasts. We verified that 18/18 human tumors of various histologies contained pronounced stromal elements staining strongly for FAP, and hypothesized that targeting tumor stroma with FAP-reactive T cells would inhibit tumor growth in cancer-bearing hosts. T cells genetically engineered with FAP-reactive chimeric antigen receptors (CARs) specifically degranulated and produced effector cytokines upon stimulation with FAP or FAP-expressing cell lines. However, adoptive transfer of FAP-reactive T cells into mice bearing a variety of subcutaneous tumors mediated limited antitumor effects and induced significant cachexia and lethal bone toxicities in two mouse strains. We found that FAP was robustly expressed on PDGFR-α+, Sca-1+ multipotent bone marrow stromal cells (BMSCs) in mice, as well as on well-characterized, clinical-grade multipotent human BMSCs. Accordingly, both mouse and human multipotent BMSCs were recognized by FAP-reactive T cells. The lethal bone toxicity and cachexia observed after cell-based immunotherapy targeting FAP cautions against its use as a universal target. Moreover, the expression of FAP by multipotent BMSCs may point toward the cellular origins of tumor stromal fibroblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche
Méndez-Ferrer, S., Michurina, T. V., Ferraro, F., Mazloom, A. R., MacArthur, B. D., Lira, S. A., Scadden, D. T., Ma’ayan, A., Enikolopov, G. N., & Frenette, P. S. (2010) · Nature · doi:10.1038/nature09262 · Cited by 3,374
Mesenchymal stem cells reside in virtually all post-natal organs and tissues
Meirelles, L. D. S., Chagastelles, P. C., & Nardi, N. B. (2006) · Journal of Cell Science · doi:10.1242/jcs.02932 · Cited by 2,485
Endothelial and perivascular cells maintain haematopoietic stem cells
Ding, L., Saunders, T. L., Enikolopov, G., & Morrison, S. J. (2012) · Nature · doi:10.1038/nature10783 · Cited by 1,954
The Pancreas Cancer Microenvironment
Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3114 · Cited by 1,316
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134 · cited 3×
“Accordingly, many groups have attempted to eradicate transformed cells by targeting fibroblast activation protein (FAP)-expressing stromal cells (Lee et al., 2005; Loeffler et al., 2006; Ostermann et al., 2008; Liao et al., 2009; Santos et al., 2009; Kraman et al., 2010; Wen et al., 2010).”
BackgroundCarcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912
Morikawa, S., Mabuchi, Y., Kubota, Y., Nagai, Y., Niibe, K., Hiratsu, E., Suzuki, S., Miyauchi-Hara, C., Nagoshi, N., Sunabori, T., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20091046 · Cited by 831
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
The elusive nature and function of mesenchymal stem cells
Nombela-Arrieta, C., Ritz, J., & Silberstein, L. E. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3049 · Cited by 670
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
The promise and potential pitfalls of chimeric antigen receptors
Sadelain, M., Brentjens, R., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 467
Scott, A. M., Wiseman, G., Welt, S., Adjei, A. A., Lee, F.-T., Hopkins, W., Divgi, C. R., Hanson, L. J., Mitchell, P., Gansen, D. N., et al. (2003) · PubMed · Cited by 438
Liao, D., Luo, Y., Markowitz, D., Xiang, R., & Reisfeld, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007965 · Cited by 437
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Santos, A. M., Jung, J., Aziz, N., Kissil, J. L., & Puré, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38988 · Cited by 428
Hofheinz, R.-D., al-Batran, S.-E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H., et al. (2003) · Oncology Research and Treatment · doi:10.1159/000069863 · Cited by 374
Narra, K., Mullins, S. R., Lee, H.-O., Strzemkowski-Brun, B., Magalong, K., Christiansen, V. J., McKee, P. A., Egleston, B., Cohen, S. J., Weiner, L. M., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.11.4874 · Cited by 275
Rettig, W. J., Garin-Chesa, P., Beresford, H. R., Oettgen, H. F., Melamed, M. R., & Old, L. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.9.3110 · Cited by 271
Welt, S., Divgi, C. R., Scott, A. M., Garin-Chesa, P., Finn, R. D., Graham, M., Carswell, E. A., Cohen, A., Larson, S. M., & Old, L. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1193 · Cited by 266
Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts
Ostermann, E., Garin-Chesa, P., Heider, K. H., Kalat, M., Lamche, H., Puri, C., Kerjaschki, D., Rettig, W. J., & Adolf, G. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5211 · Cited by 246
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 244
Self-citationWen, Y., Wang, C., Ma, T., Li, Z., Zhou, L., Mu, B., Leng, F., Shi, H., Li, Y., & Wei, Y. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01695.x · Cited by 162
Lee, J., Fassnacht, M., Nair, S., Boczkowski, D., & Gilboa, E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2805 · Cited by 159
Fibroblast Activation Protein-α
Kelly, T. J., Huang, Y., Simms, A. E., & Mazur, A. (2012) · International review of cytology · doi:10.1016/b978-0-12-394308-8.00003-0 · Cited by 144
Understanding the role of stromal fibroblasts in cancer progression
Tripathi, M., Billet, S., & Bhowmick, N. A. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20419 · Cited by 116
Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: “Are We Nearly There Yet?”
Dotti, G., Savoldo, B., & Brenner, M. K. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.142 · Cited by 98
Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
Eager, R., Cunningham, C. C., Senzer, N. N., Richards, D., Raju, R. N., Jones, B. N., Uprichard, M. J., & Nemunaitis, J. J. (2009) · Clinical Oncology · doi:10.1016/j.clon.2009.04.007 · Cited by 92
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
Eager, R. M., Cunningham, C. C., Senzer, N. N., Stephenson, J., Anthony, S. P., O'Day, S. J., Frenette, G., Pavlick, A. C., Jones, B. N., Uprichard, M. J., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-263 · Cited by 91
Fibroblast activation protein α identifies mesenchymal stromal cells from human bone marrow
Bae, S., Park, C. W., Son, H. K., Ju, H. K., Paik, D., Jeon, C., Koh, G. Y., Kim, J., & Kim, H. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07241.x · Cited by 75
The bone marrow stroma in hematological neoplasms—a guilty bystander
Tripodo, C., Sangaletti, S., Piccaluga, P. P., Prakash, S., Franco, G. M., Borrello, I., Orazi, A., Colombo, M. P., & Pileri, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.31 · Cited by 53
The establishment of a bank of stored clinical bone marrow stromal cell products
Sabatino, M., Ren, J., David‐Ocampo, V., England, L., McGann, M., Tran, M., Kuznetsov, S. A., Khuu, H. M., Balakumaran, A., Klein, H. G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-23 · Cited by 44
Cited by
The bone marrow niche for haematopoietic stem cells
Morrison, S. J., & Scadden, D. T. (2014) · Nature · doi:10.1038/nature12984 · Cited by 2,451
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Targeting cardiac fibrosis with engineered T cells
Aghajanian, H., Kimura, T., Rurik, J. G., Hancock, A. S., Leibowitz, M. S., Li, L., Scholler, J., Monslow, J., Lo, A., Han, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1546-z · Cited by 801
Metadata
- Authors
- Tran, E., Chinnasamy, D., Yu, Z., Morgan, R. A., Lee, C.-C. R., Restifo, N. P., & Rosenberg, S. A.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-05-27
- Volume
- 210
- Issue
- 6
- Pages
- 1125-1135
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2118323175
- Cited by
- 463
- References
- 30
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.